Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Rieckmann

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
Archives of Neurology|March 14, 2002
Association of a null mutation in the CNTF gene with early onset of multiple sclerosisRalf Giess, Mathias Mäurer, Ralf Linker, et al.
Expert Opinion on Pharmacotherapy|August 5, 2022
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4Sven G Meuth, Antonios Bayas, Boris Kallmann, et al.
Journal of Neurovirology|April 6, 2006
Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: implications for multiple sclerosisKlemens Ruprecht, Karola Obojes, Verena Wengel, et al.
Journal of Neurology|March 5, 2004
Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS)--a two year follow-up studyBoris-A Kallmann, Judith Sauer, Mira Schliesser, et al.
Scientific Data|January 9, 2026
PhysioMio: bilateral and longitudinal HD-sEMG dataset of 16 hand gestures from 48 stroke patientsJulian Ilg, Alexander C R Oldemeier, Marie Fieweger, et al.
The Lancet. Neurology|March 15, 2011
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysisGavin Giovannoni, Stuart Cook, Kottil Rammohan, et al.
Journal of the Neurological Sciences|March 12, 2015
ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritisRobert C Sergott, Jeffrey L Bennett, Peter Rieckmann, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY studyKottil Rammohan, Gavin Giovannoni, Giancarlo Comi, et al.
Deutsches Arzteblatt International|July 28, 2009
Multiple sclerosis registry in Germany: results of the extension phase 2005/2006Peter Flachenecker, Kristin Stuke, Wolfgang Elias, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 6, 2017
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY studyGavin Giovannoni, Per Soelberg Sorensen, Stuart Cook, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
Archives of Neurology|March 14, 2002
Association of a null mutation in the CNTF gene with early onset of multiple sclerosisRalf Giess, Mathias Mäurer, Ralf Linker, et al.
Expert Opinion on Pharmacotherapy|August 5, 2022
Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4Sven G Meuth, Antonios Bayas, Boris Kallmann, et al.
Journal of Neurovirology|April 6, 2006
Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: implications for multiple sclerosisKlemens Ruprecht, Karola Obojes, Verena Wengel, et al.
Journal of Neurology|March 5, 2004
Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS)--a two year follow-up studyBoris-A Kallmann, Judith Sauer, Mira Schliesser, et al.
Scientific Data|January 9, 2026
PhysioMio: bilateral and longitudinal HD-sEMG dataset of 16 hand gestures from 48 stroke patientsJulian Ilg, Alexander C R Oldemeier, Marie Fieweger, et al.
The Lancet. Neurology|March 15, 2011
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysisGavin Giovannoni, Stuart Cook, Kottil Rammohan, et al.
Journal of the Neurological Sciences|March 12, 2015
ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritisRobert C Sergott, Jeffrey L Bennett, Peter Rieckmann, et al.
Multiple Sclerosis and Related Disorders|April 17, 2015
Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY studyKottil Rammohan, Gavin Giovannoni, Giancarlo Comi, et al.
Deutsches Arzteblatt International|July 28, 2009
Multiple sclerosis registry in Germany: results of the extension phase 2005/2006Peter Flachenecker, Kristin Stuke, Wolfgang Elias, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 6, 2017
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY studyGavin Giovannoni, Per Soelberg Sorensen, Stuart Cook, et al.
Pageof 13